Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference
Sutro Biopharma (NASDAQ: STRO) announced five presentations at the 15th Annual World ADC Conference in San Diego, November 4-6, 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sutro Biopharma (NASDAQ: STRO) announced five presentations at the 15th Annual World ADC Conference in San Diego, November 4-6, 2024. The presentations cover various aspects of ADC innovation, including: dual-payload ADCs development, clinical updates on Luvelta targeting folate receptor, preclinical development of STRO-004, cell-free protein synthesis for site-specific conjugation, and optimization of high DAR and dual payload ADCs. The presentations will be available on Sutro's website after the event.
Details
News Market Reaction – STRO
The recorded move for STRO in the trading session of this news was +4.07%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the company will have five presentations at the 15th Annual World ADC Conference, taking place in San Diego, November 4-6, 2024.
Presentation Details:
- Development of Dual-Payload Antibody Drug Conjugates
- Presenter: Daniel Calarese, Ph.D.
- Date/Time: November 4, 2024, 2:00pm PT
- Showcasing Clinical Update & Learnings for Luvelta Targeting Folate Receptor
- Presenter: Hanspeter Gerber, Ph.D.
- Date/Time: November 5, 2024, 11:30am PT
- Characterizing ADC Safety & Activity in Preclinical Development of STRO-004
- Presenter: Alice Yam, Ph.D.
- Date/Time: November 5, 2024, 2:00pm PT
- Leveraging Cell-Free Protein Synthesis for Site- Specific Conjugation to Enhance ADC Therapeutic Index
- Presenter: Gang Yin, Ph.D.
- Date/Time: November 5, 2024, 2:30pm PT
- Optimizing High DAR & Dual Payload ADCs: Discovery of Hydrophilic β-glu Cleavable Linker Payloads for Superior Efficacy and Safety
- Presenter: Krishna Bajjuri, Ph.D.
- Date/Time: November 6, 2024, 3:00pm PT
Following the event, the content will be made available in the Clinical/Scientific Presentation and Publication Highlights section of Sutro Biopharma’s website at www.sutrobio.com.
About Sutro Biopharma
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, to transform what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates Sutro’s continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.